TIDMSCPA
RNS Number : 7510P
Scapa Group PLC
22 November 2016
22 November 2016
Scapa Group plc
Interim Results
Scapa Group plc, a global supplier of bonding solutions and
manufacturer of adhesive-based products for the Healthcare and
Industrial markets, today announces its results for the period
ended 30 September 2016.
Financial Highlights
-- Revenue grew 13.5% to GBP135.4m (2015: GBP119.3m); 3.7% at
constant exchange rates
-- Trading profit* increased 27.0% to GBP12.7m (2015: GBP10.0m);
12.4% at constant exchange rates
-- Trading profit* margins further improved to 9.4% (2015:
8.4%)
-- Adjusted profit before tax** improved 24.7% to GBP12.1m
(2015: GBP9.7m)
-- Adjusted earnings per share*** increased 28.0% to 6.4p (2015:
5.0p)
-- Basic earnings per share of 4.5p (2015: 1.4p)
-- Net debt of GBP29.0m (March 2016: GBP2.6m) reflecting the
acquisition of EuroMed for GBP28.3m
Operational Highlights
-- Healthcare revenue increased 23.3% to GBP53.5m (2015:
GBP43.4m); 11.9% at constant exchange rates
-- Healthcare trading profit increased 16.9% to GBP7.6m; 5.6%
growth at constant exchange rates
-- Margins at 14.2% (2015: 15.0%) reflecting significant
investment to support growth and integration costs related to
EuroMed
-- Healthcare acquisition of EuroMed on 23 May 2016; integrating
well
-- EuroMed and First Water significantly strengthen our
innovation and development capabilities
-- Industrial trading profit grew 49.0% to GBP7.6m; 33.3% at
constant exchange rates
-- Margins increased to 9.3% (2015: 6.7%), further improving the
quality of the business and closer to double digit margin
target
-- Swiss facility ceased production during October and will
close by the end of the calendar year, on time and on budget
-- Sale of Swiss land and building progressing well and proceeds
should exceed initial estimates
Commenting on the results Chief Executive, Heejae Chae said:
"Scapa has delivered a strong first half performance with growth
in revenue, trading profit and margins. We continue to consistently
deliver improving results in a volatile and uncertain environment.
We maintain a disciplined approach in executing our strategy and
are excited about the opportunities that exist for the business.
The Board believes the Group will deliver full year results ahead
of expectations, benefitting from both improved trading and
currency."
* Before amortisation of intangible assets, exceptional items,
pension administration costs and finance charges
** Trading profit less interest payable on bank loans and
overdrafts
*** Adjusted earnings per share is calculated by dividing the
trading profit less cash interest less tax on operating activities
by the weighted average number of ordinary shares in issue during
the year
For further information:
Scapa Group plc Heejae Chae - Chief Executive Tel: 0161 301
7430
Scapa Group plc Graham Hardcastle - Finance Director Tel: 0161
301 7430
Numis Securities Limited Mark Lander, Richard Thomas Tel: 020
7260 1000
(Nominated Adviser/Joint Broker)
Berenberg Chris Bowman Tel: 020 3207 7800
(Joint Broker)
Weber Shandwick Financial PR Nick Oborne Tel: 0207 067 0000
Strategic priorities and business objectives
Scapa has delivered a strong first half performance with growth
in revenue, trading profit and margins.
We continue to consistently deliver improving results in a
volatile and uncertain environment which affirms the robustness of
our strategy.
We operate two distinct and separate businesses each with its
own strategic goals and priorities. Healthcare - to become the
strategic Turn-Key partner for our customers leveraging the trend
of outsourcing in the Healthcare industry; and Industrial - to
maximise the Return on Capital Employed (ROCE) through operational
efficiencies and footprint consolidations as we continue to execute
our self-help agenda.
We also continue to execute our acquisition strategy to
supplement the organic growth. During the period we completed the
acquisition of EuroMed, the hydrocolloid-based wound care solutions
business based in Orangeburg, New York. The acquisition
significantly enhances our innovation and development capabilities,
which further strengthens our value chain and deepens our strategic
engagement with our Healthcare customers. EuroMed has integrated
well during the period and made a good contribution to the
Healthcare growth for the period.
Following the UK referendum on EU membership on 23 June 2016, we
have assessed the impact of the result on our business. The outcome
of this referendum is not expected to have a material near-term
impact on our business and we are well-placed to continue to grow
our global business without significant disruption. The Group
generates less than 10% of its revenues in the United Kingdom, with
50% of revenues being US Dollar based and 25% in Euros, so a
weakened Sterling would be beneficial.
Group results
Group revenue for the period increased 13.5% to GBP135.4m (2015:
GBP119.3m). Trading profit(1) for the period increased 27.0% to
GBP12.7m (2015: GBP10.0m), increasing the margin to 9.4% (2015:
8.4%). During the period, Sterling has significantly depreciated
against the US Dollar and Euro, our main trading currencies, which
had a positive translational effect on the results. Adjusting for
the effects of exchange rates, revenue increased 3.7% (2015: 4.0%)
and trading profit increased 12.4% (2015: 16.3%).
Adjusted profit before tax(2) increased 24.7% to GBP12.1m (2015:
GBP9.7m). Pre-tax profit, after exceptional items, increased to
GBP8.5m (2015: GBP3.3m). Taxation charges for the period were
GBP1.8m (2015: GBP1.2m), with the underlying effective tax rate(3)
for the period reducing to 20.7% (2015: 23.7%). The basic earnings
per share was 4.5p (2015: 1.4p). When adjusted for exceptional
items, pension administration costs, amortisation and non-cash
interest, earnings per share was 6.4p (2015: 5.0p), an increase of
28.0%.
Markets
Healthcare
30 Sept 30 Sept
Six months ended 2016 2015
---------------------- ------- -------
Revenue (GBPm) 53.5 43.4
Trading profit (GBPm) 7.6 6.5
Trading margin (%) 14.2% 15.0%
---------------------- ------- -------
The strategy of our Healthcare business is to continue to be the
strategic partner of choice for the world leading companies in
advanced wound care, consumer wellness and medical devices. The
EuroMed acquisition further strengthens our value proposition and
significantly expands our portfolio of intellectual property. We
continue to invest in our global platform, with FDA compliant
global design control procedures and FDA validated computerised
quality management systems meeting pharma standards. We have
developed a regulatory and compliance capability that is now being
offered as an outsourced service to our customers. The continued
investment enables us to accelerate the growth of our new business
pipeline, which is strong.
Revenue grew 23.3% to GBP53.5m (2015: GBP43.4m); at constant
exchange the growth rate was 11.9%. Healthcare trading profit
increased 16.9% to GBP7.6m (2015: GBP6.5m); at constant exchange
the profit increased 5.6%. The trading margin at 14.2% (2015:
15.0%) reflected significant investment to support growth and
integration costs related to EuroMed. We expect the full year
margin to be maintained at the historical level, as we continue to
drive our operating efficiency.
The integration of EuroMed, the US based Healthcare business
acquired in May 2016, is on plan and we are seeing the benefits and
opportunities of cross engagement through our customer base.
EuroMed revenue for the four months of ownership was GBP3.9m.
Industrial
30 Sept 30 Sept
Six months ended 2016 2015
----------------- ------- -------
Revenue (GBPm) 81.9 75.9
Trading profit
(GBPm) 7.6 5.1
Trading margin
(%) 9.3% 6.7%
----------------- ------- -------
Our Industrial strategy to focus on maximising ROCE has enabled
us to deliver strong results in a volatile and uncertain market
environment. Revenue grew 7.9% to GBP81.9m (2015: GBP75.9m).
Trading profit for the period was GBP7.6m (2015: GBP5.1m), an
increase of 49.0% over the prior period with the trading margin
increasing to 9.3% (2015: 6.7%). After adjusting for the effect of
exchange rates, revenue declined by 1.1% and profit grew 33.3%,
reflecting the improvement in operational efficiency and lower
input costs.
The closure of our Rorschach site in Switzerland, which we
announced in April 2015, is progressing in line with plan. The site
ceased production during October and will close by the end of the
calendar year after remediation and disposals. We remain confident
in our forecasts that the closure will add an underlying GBP2.0m of
trading profit per year to the Group, with GBP1.0m expected in the
second half of 2016/17. Additionally, the auction process for the
sale of the land is progressing well and post certain remediation
we expect to generate proceeds above the initial estimates.
Exceptional items
The exceptional expenses in the period relate to the Company's
decision in July 2015 to close its Rorschach facility and the
acquisition in May 2016 of EuroMed. The acquisition costs are those
costs directly related to the purchase of EuroMed. The site closure
costs are made up of retention payments made to certain key staff
and a small additional impairment of fixed assets. Both items are
reported separately to give a better understanding of the Company's
underlying performance.
Balance sheet
Net assets at 30 September 2016 totalled GBP80.9m (31 March
2016: GBP77.7m). The slight increase arises from improved retained
earnings of GBP6.7m and positive foreign exchange movements of
GBP9.8m offset by negative actuarial movements of GBP11.6m and
share related items of GBP1.8m. The Group net debt balance was
GBP29.0m (31 March 2016: GBP2.6m) after a net cash outflow of
GBP26.4m in the period, principally reflecting the acquisition cost
of EuroMed for GBP28.3m.
Pensions
The pension deficit increased to GBP38.0m (31 March 2016:
GBP27.5m). The increase in the deficit is owing to the decrease in
the interest rate used to discount the long-term liabilities; it
fell significantly from 3.5% at March 2016 to 2.2% at September
2016. Cash payments of GBP2.2m (September 2015: GBP2.1m) and
liability matching asset investment gains mitigated the effect of
the change.
Cash resources
Net cash generated from operations was GBP11.2m (2015: GBP6.8m).
Trading working capital increased by GBP0.1m (2015: GBP1.5m), owing
to some additional inventory associated with transferring
activities from Rorschach. Capital expenditure in the period was
GBP4.6m (2015: GBP5.6m) down slightly from the prior year despite
capital expenditure due to the transfer. Pension payments in excess
of operating charge were GBP2.2m (2015: GBP2.1m) and represent the
deficit repair payments and contributions to scheme expenses. Tax
and interest outflows were GBP2.4m (2015: GBP2.2m), with the
increase being mainly the interest on increased debt after the
acquisition of EuroMed for GBP28.3m. After dividends of GBP2.6m
(2015: GBP2.2m), closing net debt was GBP29.0m, less than 1x LTM
EBITDA(4) (31 March 2016: GBP2.6m net debt).
Dividend
A final dividend for the year ended 31 March 2016 of 1.75p per
share was paid on 19 August 2016 to all shareholders registered on
22 July 2016. In line with last year, the Board does not propose an
interim dividend but intends to maintain a progressive dividend
policy.
Principal risks and uncertainties
There are a number of potential risks and uncertainties which
could have a material impact on the Group's performance over the
remaining six months of the financial year and could cause actual
results to differ materially from expected and historical results.
The Directors do not consider that these principal risks and
uncertainties have changed since publication of the annual report
for the year ended 31 March 2016.
Going concern
As stated in note 1 to these condensed financial statements, the
Directors are satisfied that the Group has sufficient resources to
continue in operation for the foreseeable future, a period of not
less than 12 months from the date of this report. Accordingly, they
continue to adopt the going concern basis in preparing these
condensed financial statements.
Summary and outlook
Scapa has delivered a strong first half performance with growth
in revenue, trading profit and margins. We continue to consistently
deliver improving results in a volatile and uncertain environment.
We maintain a disciplined approach in executing our strategy and
are excited about the opportunities that exist for the business.
The Board believes the Group will deliver full year results ahead
of expectations, benefitting from both improved trading and
currency.
J A S Wallace
Chairman
(1) Before amortisation of intangible assets, exceptional items,
pension administration costs and finance charges.
(2) Trading profit less interest payable on bank loans and
overdrafts.
(3) Adjusting operating profit and taxation for exceptional
items, pension administration costs, amortisation and non-cash
interest.
(4) As defined in Note 22 of the Annual Report.
Consolidated Income Statement
For the half year ended 30 September 2016 (unaudited)
Half year Half year
ended ended Year ended
30 Sept 30 Sept 31 Mar
All on continuing 2016 2015 2016
operations note GBPm GBPm GBPm
----------------------- ---- --------- --------- ----------
Revenue 2 135.4 119.3 246.7
Operating pro t 2 9.5 4.1 11.7
----------------------- ---- --------- --------- ----------
Trading profit* 12.7 10.0 21.3
----------------------- ---- --------- --------- ----------
Amortisation of
intangible assets (1.9) (1.2) (2.3)
Exceptional items 4 (1.0) (4.3) (6.6)
Pension administration
costs (0.3) (0.4) (0.7)
Operating profit 2 9.5 4.1 11.7
----------------------- ---- --------- --------- ----------
Finance costs 7 (1.0) (0.8) (1.9)
----------------------- ---- --------- --------- ----------
Pro t on ordinary
activities before
tax 8.5 3.3 9.8
Taxation charge 8 (1.8) (1.2) (3.7)
Pro t for the period 6.7 2.1 6.1
----------------------- ---- --------- --------- ----------
Weighted average
number of shares
(m) 150.4 147.3 148.3
----------------------- ---- --------- --------- ----------
Basic earnings per
share (p) 4.5 1.4 4.1
----------------------- ---- --------- --------- ----------
Diluted earnings
per share (p) 4.3 1.4 3.9
----------------------- ---- --------- --------- ----------
Adjusted earnings
per share (p) 6.4 5.0 10.6
----------------------- ---- --------- --------- ----------
* Before amortisation of intangible assets, exceptional items,
pension administration costs and finance charges.
Consolidated Statement of Comprehensive Income
For the half year ended 30 September 2016 (unaudited)
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
--------------------------------------------------------------------- --------------- --------------- ----------
Profit for the period 6.7 2.1 6.1
--------------------------------------------------------------------- --------------- --------------- ----------
Items that may be reclassified subsequently to profit and loss:
Exchange differences on translating foreign operations 9.8 (2.5) 2.5
Actuarial (loss)/gain (11.6) 5.9 7.9
Items that will not be reclassified subsequently to profit and loss:
Deferred tax on actuarial (gain)/loss - - (0.2)
Other (expense)/income for the period (1.8) 3.4 10.2
--------------------------------------------------------------------- --------------- --------------- ----------
Total comprehensive income for the period 4.9 5.5 16.3
--------------------------------------------------------------------- --------------- --------------- ----------
Consolidated Balance Sheet
As at 30 September 2016 (unaudited)
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
note GBPm GBPm GBPm
---------------------------------------------- ---- --------------- --------------- ----------
Assets
Non-current assets
Goodwill 54.5 33.4 34.7
Intangible assets 8.3 4.5 3.4
Property, plant and equipment 53.5 42.5 46.1
Deferred tax asset 8.0 8.7 7.6
Other receivables 0.1 - -
124.4 89.1 91.8
Current assets
Inventory 33.9 27.7 27.1
Trade and other receivables 51.3 43.4 47.9
Current tax asset 1.5 1.0 0.6
Cash and cash equivalents 14 12.4 15.9 18.7
---------------------------------------------- ---- --------------- --------------- ----------
99.1 88.0 94.3
Liabilities
Current liabilities
Financial liabilities:
- Borrowings and other nancial liabilities (1.4) (0.9) (1.0)
Trade and other payables (48.9) (42.3) (45.2)
Deferred consideration (0.1) (0.1) (0.1)
Current tax liabilities (0.1) (0.2) (0.2)
Provisions 13 (2.5) (4.2) (3.9)
---------------------------------------------- ---- --------------- --------------- ----------
(53.0) (47.7) (50.4)
---------------------------------------------- ---- --------------- --------------- ----------
Net current assets 46.1 40.3 43.9
---------------------------------------------- ---- --------------- --------------- ----------
Non-current liabilities
Financial liabilities:
- Borrowings and other financial liabilities (40.0) (21.8) (20.3)
Trade and other payables (0.2) (0.2) (0.2)
Deferred consideration - (0.1) (0.1)
Deferred tax liabilities (6.8) (6.5) (6.4)
Non-current tax liabilities (2.4) (2.0) (2.0)
Retirement bene t obligations 12 (38.0) (31.7) (27.5)
Provisions 13 (2.2) (1.4) (1.5)
---------------------------------------------- ---- --------------- --------------- ----------
(89.6) (63.7) (58.0)
---------------------------------------------- ---- --------------- --------------- ----------
Net assets 80.9 65.7 77.7
---------------------------------------------- ---- --------------- --------------- ----------
Shareholders' equity
Ordinary shares 7.6 7.4 7.5
Share premium 0.4 0.4 0.4
Retained earnings 42.6 42.4 49.3
Translation reserve 30.3 15.5 20.5
Total shareholders' equity 80.9 65.7 77.7
---------------------------------------------- ---- --------------- --------------- ----------
Consolidated Statement of Changes in Equity
For the half year ended 30 September 2016 (unaudited)
Share Share Total
capital premium Translation reserves Retained earnings equity
GBPm GBPm GBPm GBPm GBPm
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Balance at 31 March 2015 7.4 0.4 18.0 36.0 61.8
Employee share option scheme -
value of employee services - - - 0.6 0.6
Dividends to shareholders - - - (2.2) (2.2)
- - - (1.6) (1.6)
Currency translation differences - - (2.5) - (2.5)
Actuarial gain on pension schemes - - - 5.9 5.9
Net (expense)/income recognised directly in
equity - - (2.5) 5.9 3.4
Profit for the period - - - 2.1 2.1
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Total comprehensive (expense)/income - - (2.5) 8.0 5.5
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Balance at 30 September 2015 7.4 0.4 15.5 42.4 65.7
Employee share option scheme -
value of employee services - - - 1.2 1.2
Equity-settled share based payments - - - (0.1) (0.1)
Issue of shares 0.1 - - - 0.1
0.1 - - 1.1 1.2
Currency translation differences - - 5.0 - 5.0
Actuarial gain on pension schemes - - - 2.0 2.0
Deferred tax on actuarial gain - - - (0.2) (0.2)
Net income recognised directly in equity - - 5.0 1.8 6.8
Profit for the period - - - 4.0 4.0
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Total comprehensive income - - 5.0 5.8 10.8
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Balance at 31 March 2016 7.5 0.4 20.5 49.3 77.7
Employee share option scheme -
value of employee services - - - 0.9 0.9
Equity-settled share based payments - - - (0.1) (0.1)
Dividends - - - (2.6) (2.6)
Issue of shares 0.1 - - - 0.1
------------------------------------------------ -------- -------- -------------------- ----------------- -------
0.1 - - (1.8) (1.7)
Currency translation differences - - 9.8 - 9.8
Actuarial loss on pension schemes - - - (11.6) (11.6)
Net income/(expense) recognised directly in
equity - - 9.8 (11.6) (1.8)
Profit for the period - - - 6.7 6.7
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Total comprehensive income/(expense) - - 9.8 (4.9) 4.9
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Balance at 30 September 2016 7.6 0.4 30.3 42.6 80.9
------------------------------------------------ -------- -------- -------------------- ----------------- -------
Consolidated Cash Flow Statement
For the half year ended 30 September 2016 (unaudited)
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
All on continuing operations note GBPm GBPm GBPm
--------------------------------------------- ---- --------------- --------------- ----------
Cash flows from operating activities
Net cash ow from operations 14 11.2 6.8 16.5
--------------------------------------------- ---- --------------- --------------- ----------
Cash generated from operations before
exceptional items* 14 13.4 7.0 19.0
Cash out ows from exceptional items* 14 (2.2) (0.2) (2.5)
--------------------------------------------- ---- --------------- --------------- ----------
Net cash ow from operations 11.2 6.8 16.5
--------------------------------------------- ---- --------------- --------------- ----------
Net interest paid (0.5) (0.3) (0.6)
Income tax paid (1.9) (1.9) (3.0)
--------------------------------------------- ---- --------------- --------------- ----------
Net cash generated from operating activities 8.8 4.6 12.9
--------------------------------------------- ---- --------------- --------------- ----------
Cash ows (used in)/from investing activities
Acquisition of subsidiary 11 (28.3) - -
Purchase of property, plant and equipment (4.6) (5.6) (9.8)
Proceeds from sale of property, plant
and equipment - 0.1 0.1
--------------------------------------------- ---- --------------- --------------- ----------
Net cash used in investing activities (32.9) (5.5) (9.7)
--------------------------------------------- ---- --------------- --------------- ----------
Cash ows (used in)/from financing activities
Dividends (2.6) (2.2) (2.2)
Increase in borrowings 20.8 3.0 5.7
Repayment of borrowings (1.3) (0.4) (4.9)
--------------------------------------------- ---- --------------- --------------- ----------
Net cash from/(used in) financing activities 16.9 0.4 (1.4)
--------------------------------------------- ---- --------------- --------------- ----------
Net (decrease)/increase in cash
and cash equivalents (7.2) (0.5) 1.8
Cash and cash equivalents at beginning
of the period 18.7 16.7 16.7
Exchange gains on cash and cash equivalents 0.9 (0.3) 0.2
--------------------------------------------- ---- --------------- --------------- ----------
Cash and cash equivalents at end of period 14 12.4 15.9 18.7
--------------------------------------------- ---- --------------- --------------- ----------
* Exceptional items include provision movements on items charged
to the Income Statement in prior years.
Notes
1. General information
Scapa Group plc ('the Company') and its subsidiaries (together
'the Group') manufacture bonding products and adhesive components
for applications in the healthcare and industrial markets. The
Group has manufacturing plants around the world and sells mainly in
countries within Europe, North America and Asia.
The Company is a limited liability company incorporated and
domiciled in the UK. The address of its registered office is 997
Manchester Road, Ashton-under-Lyne, Greater Manchester OL7 0ED. The
Company has its listing on the Alternative Investment Market.
The financial information for the period ended 30 September 2016
and similarly the period ended 30 September 2015 has been neither
audited nor reviewed by the auditor. The financial information for
the year ended 31 March 2016 has been based on information in the
audited financial statements for that period.
The information for the year ended 31 March 2016 and the interim
condensed financial statements for the period ended 30 September
2016 do not constitute statutory accounts as defined in section 434
of the Companies Act 2006. A copy of the statutory accounts for the
year ended 31 March 2016 has been delivered to the Registrar of
Companies. The auditor's report on those accounts was not
qualified, did not include a reference to any matters to which the
auditor drew attention by way of emphasis without qualifying the
report and did not contain statements under section 498 (2) or (3)
of the Companies Act 2006.
Basis of preparation
The consolidated financial statements for Scapa Group plc are
prepared in accordance with IFRSs as adopted by the European Union.
AIM listed companies are not required to issue IAS 34 compliant
interim reports. Scapa Group plc complies with the majority of IAS
34 but does not produce a number of additional disclosures that are
not considered significant.
Accounting policies
The same accounting policies, presentation and methods of
computation are followed in the interim condensed financial
statements as applied in the Group's latest annual audited
financial statements.
Critical accounting estimates, judgements and risks
The preparation of the interim condensed financial statements
requires management to make judgements, estimates and assumptions
that affect the application of accounting policies and the reported
amounts of assets and liabilities, income and expense. Actual
results may differ from these estimates.
In preparing these interim condensed financial statements, the
significant judgements made by management in applying the Group's
accounting policies and the key sources of estimation uncertainty
were the same as those that applied to the consolidated financial
statements for the year ended 31 March 2016.
A summary of the principal risks and uncertainties is below and
a more detailed explanation and how the Group seeks to mitigate the
risks can be found on pages 12 to 18 of the Annual Report, which is
available at www.scapa.com.
Health and safety - failure to work safely could damage the
reputation of the Group and incur regulator intervention or
fines
Acquisitions - poor decision-making on acquisitions could
adversely affect the Group's results, weakening shareholder
value
Business strategy - development of the wrong strategy by the
Board or the failure to implement its strategy effectively could
negatively impact on the Group's long-term growth plan
Financial and treasury - the Group has significant operations
outside the UK and as such is exposed to movement in exchange
rates
Pensions - retirement liabilities fluctuate with changes in life
expectancy, inflation, asset performance and discount rate
assumptions
Customers - the Group benefits from good commercial
relationships with a number of key customers. Damage to these
relationships could have a direct, detrimental effect on the
Group's results
Raw material pricing - Group margin is susceptible to supplier
price increases
Human resources - availability of sufficient, skilled resource
may impact on our ability to achieve sustainable growth
ICT systems and infrastructure - the Group is reliant on ICT
systems in the effective planning and manufacture of product.
Significant disruption can interrupt manufacturing and support
process and potentially impact sales
Product quality - the Group is exposed to financial risk around
product liability, customer returns and ultimately customer trust
in Scapa as a supplier
Environment - failure to mitigate environmental impacts could
damage the reputation of the Group and result in the financial loss
associated with clean-up, fines and sanctions
Going concern
The Directors are satisfied that the Group's forecasts and
projections show that the Group should be able
to operate within its banking facilities and comply with its
banking covenants. The Group is exposed to a number of significant
risks and uncertainties, which could affect the Group's ability to
meet its banking covenants. The Directors have a reasonable
expectation that the Group has adequate resources to continue in
operational existence for a period of not less than 12 months from
the date of this report. Accordingly, they continue to adopt the
going concern basis in preparing the interim condensed financial
statements.
2. Segmental reporting
The Group operates two standalone business units: Healthcare and
Industrial, supported by a strategic Corporate function. All
inter-segment transactions are made on an arm's length basis.
The chief operating decision maker relies primarily on turnover
and trading profit to assess the performance of the Group and makes
decisions about resources to be allocated to each segment; assets
and liabilities are looked at geographically. Trading profit is
reconciled to operating profit on the face of the Income
Statement.
The Board reviews the performance of the business using
information presented at constant exchange rates. The prior year
results have been restated at constant currency as shown on the
following pages.
Segment results - 30 September 2016
The segment results for the half year ended 30 September 2016
are as follows:
Healthcare Industrial Head office Group
GBPm GBPm GBPm GBPm
---------------------------------- ---------- ---------- ----------- -----
External revenue 53.5 81.9 - 135.4
---------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) 7.6 7.6 (2.5) 12.7
Amortisation of intangible assets (1.9) - - (1.9)
Exceptional items (0.6) (0.4) - (1.0)
Pension administration costs - - (0.3) (0.3)
---------------------------------- ---------- ---------- ----------- -----
Operating profit/(loss) 5.1 7.2 (2.8) 9.5
Net finance costs (1.0)
---------------------------------- ---------- ---------- ----------- -----
Profit on ordinary activities before tax 8.5
Tax charge (1.8)
---------------------------------------------------------- ----------- -----
Profit for the period 6.7
---------------------------------------------------------- ----------- -----
Revenue is allocated based on the country in which the order is
received. The revenue analysis based on the location of the
customer is as follows:
Europe N America Asia Other Group
GBPm GBPm GBPm GBPm GBPm
-------------------------------- ------ --------- ----- ----- -----
External revenue - 30 Sept 2016 53.8 67.2 6.3 8.1 135.4
-------------------------------- ------ --------- ----- ----- -----
External revenue - 30 Sept 2015 44.1 59.6 7.3 8.3 119.3
-------------------------------- ------ --------- ----- ----- -----
External revenue - 31 Mar 2016 95.4 121.0 15.1 15.2 246.7
-------------------------------- ------ --------- ----- ----- -----
The revenue based on the location where the sale occurred is as
follows:
Europe N America Asia Other Group
GBPm GBPm GBPm GBPm GBPm
-------------------------------- ------ --------- ----- ----- -----
External revenue - 30 Sept 2016 55.5 72.5 6.4 1.0 135.4
-------------------------------- ------ --------- ----- ----- -----
External revenue - 30 Sept 2015 49.3 62.0 7.3 0.7 119.3
-------------------------------- ------ --------- ----- ----- -----
External revenue - 31 Mar 2016 101.9 129.3 14.0 1.5 246.7
-------------------------------- ------ --------- ----- ----- -----
Segment results - 30 September 2015
The segment results for the half year ended 30 September 2015
are as follows:
Healthcare Industrial Head office Group
GBPm GBPm GBPm GBPm
---------------------------------- ---------- ---------- ----------- -----
External revenue 43.4 75.9 - 119.3
---------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) 6.5 5.1 (1.6) 10.0
Amortisation of intangible assets (1.2) - - (1.2)
Exceptional items - (4.7) 0.4 (4.3)
Pension administration costs - (0.1) (0.3) (0.4)
---------------------------------- ---------- ---------- ----------- -----
Operating profit/(loss) 5.3 0.3 (1.5) 4.1
Net finance costs (0.8)
---------------------------------- ---------- ---------- ----------- -----
Profit on ordinary activities before tax 3.3
Tax charge (1.2)
---------------------------------------------------------- ----------- -----
Profit for the period 2.1
---------------------------------------------------------- ----------- -----
The Board reviews the performance of the business using
information presented at constant exchange rates. The prior half
year results have been restated using this year's exchange rates as
follows:
Healthcare Industrial Head office Group
GBPm GBPm GBPm GBPm
------------------------------------------------- ---------- ---------- ----------- -----
External revenue 43.4 75.9 - 119.3
Foreign exchange 4.4 6.9 - 11.3
------------------------------------------------- ---------- ---------- ----------- -----
External revenue at constant exchange rates 47.8 82.8 - 130.6
------------------------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) 6.5 5.1 (1.6) 10.0
Foreign exchange 0.7 0.6 - 1.3
------------------------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) at constant exchange rates 7.2 5.7 (1.6) 11.3
------------------------------------------------- ---------- ---------- ----------- -----
Segment results - 31 March 2016
The segment results for the year ended 31 March 2016 are as
follows:
Healthcare Industrial Head office Group
GBPm GBPm GBPm GBPm
---------------------------------- ---------- ---------- ----------- -----
External revenue 93.3 153.4 - 246.7
---------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) 14.0 10.7 (3.4) 21.3
Amortisation of intangible assets (2.3) - - (2.3)
Exceptional items (1.5) (4.6) (0.5) (6.6)
Pension administration costs - - (0.7) (0.7)
---------------------------------- ---------- ---------- ----------- -----
Operating profit/(loss) 10.2 6.1 (4.6) 11.7
Net finance costs (1.9)
---------------------------------- ---------- ---------- ----------- -----
Profit on ordinary activities before tax 9.8
Tax charge (3.7)
---------------------------------------------------------- ----------- -----
Profit for the year 6.1
---------------------------------------------------------- ----------- -----
The Board reviews the performance of the business using
information presented at constant exchange rates. The prior year
results have been restated using this year's exchange rates as
follows:
Healthcare Industrial Head office Group
GBPm GBPm GBPm GBPm
------------------------------------------------- ---------- ---------- ----------- -----
External revenue 93.3 153.4 - 246.7
Foreign exchange 6.5 13.3 - 19.8
------------------------------------------------- ---------- ---------- ----------- -----
External revenue at constant exchange rates 99.8 166.7 - 266.5
------------------------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) 14.0 10.7 (3.4) 21.3
Foreign exchange 1.2 1.2 - 2.4
------------------------------------------------- ---------- ---------- ----------- -----
Trading profit/(loss) at constant exchange rates 15.2 11.9 (3.4) 23.7
------------------------------------------------- ---------- ---------- ----------- -----
3. Segment assets and liabilities
The chief operating decision maker does not review assets and
liabilities by business unit but by geographical area. The assets
and liabilities at 30 September 2016 and capital expenditure for
the period then ended can be analysed into geographical segments as
follows:
Europe N America Asia Head office Group
GBPm GBPm GBPm GBPm GBPm
------------------------------------------- ------ --------- ----- ----------- ------
Non-current assets* 36.2 76.1 4.1 - 116.4
Inventory 15.2 15.7 3.0 - 33.9
Trade receivables (net) 20.8 24.3 1.7 - 46.8
Trade payables (21.4) (10.9) (0.6) (0.4) (33.3)
Cash 6.0 4.6 1.9 (0.1) 12.4
Additions of property, plant and equipment 2.4 2.1 0.1 - 4.6
------------------------------------------- ------ --------- ----- ----------- ------
* Non-current assets excluding deferred tax assets.
The assets and liabilities at 30 September 2015 and capital
expenditure for the period then ended were as follows:
Europe N America Asia Head office Group
GBPm GBPm GBPm GBPm GBPm
------------------------------------------- ------ --------- ----- ----------- ------
Non-current assets* 32.7 44.8 2.9 - 80.4
Inventory 12.4 13.0 2.3 - 27.7
Trade receivables (net) 17.9 19.5 3.5 - 40.9
Trade payables (17.4) (11.5) (0.7) (0.4) (30.0)
Cash 8.0 4.7 1.6 1.6 15.9
Additions of property, plant and equipment 2.9 1.2 1.6 - 5.7
------------------------------------------- ------ --------- ----- ----------- ------
* Non-current assets excluding deferred tax assets.
The assets and liabilities at 31 March 2016 and capital
expenditure for the year then ended were as follows:
Europe N America Asia Head office Group
GBPm GBPm GBPm GBPm GBPm
------------------------------------------- ------ --------- ----- ----------- ------
Non-current assets* 34.2 46.4 3.6 - 84.2
Inventory 11.9 13.0 2.2 - 27.1
Trade receivables (net) 22.1 20.0 1.2 - 43.3
Trade payables (19.8) (9.2) (0.5) (0.5) (30.0)
Cash 6.6 3.5 1.8 6.8 18.7
Additions of property, plant and equipment 5.2 2.3 2.0 0.2 9.7
------------------------------------------- ------ --------- ----- ----------- ------
* Non-current assets excluding deferred tax assets.
Unallocated head office items relate to assets and liabilities
incurred in the normal course of business for the Parent
Company.
4. Exceptional items
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
---------------------------------------------- --------------- --------------- ----------
Operating income:
UK pension settlement gain - 0.6 0.6
US pension settlement gain - - 1.0
Bellegarde land sale - - 0.5
Operating expenses:
Site closure costs (0.3) (3.4) (3.5)
Asset write-offs and accelerated depreciation (0.1) (1.5) (1.6)
Post-combination remuneration - - (2.0)
Reorganisation costs - - (1.2)
Abortive acquisition costs - - (0.4)
Acquisition costs (0.6) - -
(1.0) (4.3) (6.6)
---------------------------------------------- --------------- --------------- ----------
During the period costs have been incurred on the closure of our
Rorschach site in Switzerland and on the purchase of EuroMed. To
enable readers of the accounts to better understand the underlying
performance of the business, these one-off costs have been
separated out on the face of the income statement.
The acquisition costs are directly related to the acquisition of
EuroMed and are covered in note 11.
The closure of the Rorschach site in Switzerland was announced
in April 2015 and substantially provided for in the 2016 accounts.
However certain costs have been incurred in the period that could
not be provided for previously: being retention payments made to
certain key members of staff of GBP0.3m and GBP0.1m impairment of
assets that continued to be used up until cessation of production
at the site.
The prior year costs relate entirely to the closure of our
Rorschach site and include the impairment of plant and machinery
down to its recoverable value, GBP1.5m, and the then best estimate
of costs to close the site of GBP3.4m. The closure costs included
all the employee and employee consultation costs, the remediation
and building strip-out costs, the legal costs associated with
closing the site and certain costs related to revalidating a number
of products at alternative sites, essential to ensure the continued
production within the Group. These estimates remain our best
estimate and no additional provisions have been made in the period.
In the future certain costs may be incurred to enhance the site if
it is deemed economic to attain a higher final sale price.
5. Key management compensation and Directors' remuneration
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
------------------------------------------------------ --------------- --------------- ----------
Short-term employment benefits 2.6 1.8 4.1
Post-employment benefits 0.1 0.1 0.2
Termination benefits - 0.2 0.2
Share-based payments (including share incentive plan) 0.8 0.8 1.6
------------------------------------------------------ --------------- --------------- ----------
3.5 2.9 6.1
------------------------------------------------------ --------------- --------------- ----------
Key management is considered by the Group to be the Executive
Team, which comprises certain senior employees, as defined in the
annual financial statements.
The short-term employment benefits include wages and salaries,
bonuses, social security contributions and non-monetary
benefits.
6. Related party transactions
The pension schemes are related parties to the Group. There were
no contributions outstanding at the period end.
7. Net finance costs
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
------------------------------------------------------------------------ --------------- --------------- ----------
Interest payable on bank loans and overdrafts (0.6) (0.3) (0.7)
Expected return on pension scheme assets less interest on scheme
liabilities (0.4) (0.5) (1.2)
Net finance costs (1.0) (0.8) (1.9)
------------------------------------------------------------------------ --------------- --------------- ----------
8. Taxation
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
-------------------------------------------- --------------- --------------- ----------
Current tax:
Tax on trading activities - current period (1.7) (1.4) (3.0)
Tax on trading activities - prior period 0.1 0.2 0.4
Tax on non-trading items - 0.4 0.2
-------------------------------------------- --------------- --------------- ----------
Total current tax (1.6) (0.8) (2.4)
-------------------------------------------- --------------- --------------- ----------
Deferred tax:
Tax on trading activities - current period (0.6) (1.1) (2.4)
Tax on trading activities - prior period (0.3) - 0.1
Tax on non-trading items 0.7 0.7 1.0
Total deferred tax (0.2) (0.4) (1.3)
-------------------------------------------- --------------- --------------- ----------
Tax charge on trading activities (2.5) (2.3) (4.9)
-------------------------------------------- --------------- --------------- ----------
Tax income on non-trading activities 0.7 1.1 1.2
-------------------------------------------- --------------- --------------- ----------
Tax charge for the period (1.8) (1.2) (3.7)
-------------------------------------------- --------------- --------------- ----------
9. Earnings per share
Basic
Basic earnings per share is calculated by dividing the profit
attributable to equity holders of the Company by the weighted
average number of ordinary shares in issue during the period.
Diluted
Diluted earnings per share is calculated by adjusting the
weighted average number of ordinary shares outstanding to assume
conversion of all potentially dilutive ordinary shares. Diluted
earnings per share has been calculated on share options in
existence at 30 September 2016.
Adjusted
Adjusted earnings per share is calculated by dividing the
trading profit less cash interest less tax on operating activities
by the weighted average number of ordinary shares in issue during
the period.
Half year ended Half year ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
------------------------------------------------------------------------ --------------- --------------- ----------
Profit attributable to equity holders of the Company (GBPm) 6.7 2.1 6.1
Weighted average number of ordinary shares in issue (m) 150.4 147.3 148.3
Basic earnings per share (p) 4.5 1.4 4.1
Weighted average number of shares in issue, including potentially
dilutive shares (m) 157.3 154.1 157.3
Diluted earnings per share (p) 4.3 1.4 3.9
Adjusted earnings per share (p) 6.4 5.0 10.6
------------------------------------------------------------------------ --------------- --------------- ----------
10. Dividends
A final dividend for the year ended 31 March 2016 of 1.75p per
share was declared by the Directors at their meeting on 23 May
2016. The dividend was paid on 19 August 2016 to shareholders
registered on 22 July 2016.
11. Acquisition of subsidiary
On 23 May 2016 the Group acquired 100% of the share capital of
EuroMed, obtaining control. EuroMed is a hydrocolloid-based wound
care solutions provider. The Company is based in New York
State.
The Directors believe that the acquisition of EuroMed brings
multiple advantages to Scapa, including:
-- Proprietary and patented technology to broaden and strengthen
Scapa Healthcare's Turn-Key value proposition
-- Innovative R&D capabilities complementing Scapa
Healthcare's existing resources
-- Expanded opportunities for growth in new markets and with new
customers
-- Significant cross-selling opportunities across the customer
base
-- Improved manufacturing infrastructure
-- Acceleration in Scapa Healthcare's growth
-- The acquisition is expected to be earnings enhancing in the
first full year in the enlarged Group.
The amounts recognised in respect of the identifiable assets
acquired and liabilities assumed are as set out in the table
below:
Fair Value
GBPm
------------------------------------------ ----------
Net assets acquired
Separately identifiable intangible assets 6.5
Property, plant and machinery 1.9
Other assets 0.1
Inventory 2.1
Debt, cash and equivalents 3.2
Trade and other payables (2.3)
------------------------------------------ ----------
11.5
Goodwill 16.8
Total consideration 28.3
------------------------------------------ ----------
Satisfied by cash 28.3
In addition to the above, the former owners of the business have
the opportunity to earn an additional US$7.0m (GBP GBP5.4m)
consideration based on the future performance of EuroMed. None of
the consideration has been recognised as current forecasts suggest
that the targets for payment will not be met.
The goodwill of GBP16.8m arising from the acquisition is
expected to be deductible for income tax purposes in the US.
Acquisition related costs (included within exceptionals) amount to
GBP0.6m.
12. Retirement benefit schemes
Defined benefit schemes
The defined benefit obligation as at 30 September 2016 is
calculated by rolling forward the March 2016 valuation and
adjusting for movements over the period.
The defined benefit plan assets have been updated to reflect
their market value at 30 September 2016. Differences between the
expected return on assets have been recognised as an actuarial gain
or loss in the Statement of Comprehensive Income in accordance with
the Group's accounting policy.
13. Provisions
Reorganisation
and leasehold
commitments Environmental Total
GBPm GBPm GBPm
------------------------ --------------- ------------- -----
At 31 March 2015 1.7 0.7 2.4
Charged in the period 3.6 - 3.6
Utilised in the period (0.1) (0.3) (0.4)
At 30 September 2015 5.2 0.4 5.6
Exchange differences 0.2 - 0.2
Charged in the period 1.3 0.1 1.4
Released in the period - (0.3) (0.3)
Utilised in the period (1.7) 0.2 (1.5)
At 31 March 2016 5.0 0.4 5.4
Exchange differences 0.2 - 0.2
Charged in the period 0.7 - 0.7
Utilised in the period (1.5) (0.1) (1.6)
-------------------------- -------------- ------------- -----
At 30 September 2016 4.4 0.3 4.7
-------------------------- -------------- ------------- -----
Analysis of provisions:
Current 2.2 0.3 2.5
Non-current 2.2 - 2.2
-------------------------- -------------- ------------- -----
At 30 September 2016 4.4 0.3 4.7
-------------------------- -------------- ------------- -----
14. Reconciliation of operating profit to operating cash flow
and reconciliation of net cash
Half year Half year
ended ended Year ended
30 Sept 30 Sept 31 Mar
2016 2015 2016
GBPm GBPm GBPm
------------------------------- --------- --------- ----------
Operating profit 9.5 4.1 11.7
Adjustments for:
Depreciation and amortisation 4.8 3.7 7.5
Exceptional pension
settlement - (0.6) (1.6)
Impairment of tangible
fixed assets 0.3 1.5 1.6
Pensions payments in
excess of charge (2.2) (2.1) (4.4)
Share options charge 0.8 0.6 1.8
Grant income released - (0.1) (0.1)
Changes in working
capital:
------------------------------- --------- --------- ----------
Inventories (2.7) (3.4) (1.7)
Trade debtors 2.7 0.9 0.9
Trade creditors (0.1) 1.0 (0.4)
------------------------------- --------- --------- ----------
Changes in trading
working capital (0.1) (1.5) (1.2)
Other debtors 0.5 0.6 (1.1)
Other creditors (1.5) (2.7) (0.4)
Deferred consideration - - (0.1)
Net movement in environmental
provisions (0.1) (0.2) (0.3)
Net movement in reorganisation
provisions and
leasehold commitments (0.1) - 0.2
Net movement in other
provisions (0.7) 3.5 2.9
Cash generated from
operations 11.2 6.8 16.5
------------------------------- --------- --------- ----------
Cash generated from
operations before exceptional
items 13.4 7.0 19.0
Cash outflows from
exceptional items (2.2) (0.2) (2.5)
------------------------------- --------- --------- ----------
Cash generated from
operations 11.2 6.8 16.5
------------------------------- --------- --------- ----------
Analysis of cash and cash equivalents and borrowings
At 1 April Cash At 30 Sept
2016 flow Exchange movement 2016
GBPm GBPm GBPm GBPm
------------------------------------ ---------- ------ ----------------- ----------
Cash and cash equivalents 18.7 (7.2) 0.9 12.4
Borrowings within one year (1.0) (0.3) (0.1) (1.4)
Borrowings after more than one year (20.3) (19.2) (0.5) (40.0)
------------------------------------ ---------- ------ ----------------- ----------
Total borrowings (21.3) (19.5) (0.6) (41.4)
------------------------------------ ---------- ------ ----------------- ----------
Total (2.6) (26.7) 0.3 (29.0)
------------------------------------ ---------- ------ ----------------- ----------
Key dates
Next year end (to be reported) 31 March 2017
Next preliminary announcement 23 May 2017
Next annual report due June 2017
Next Annual General Meeting 18 July 2017
Next interim results 21 November 2017
Shareholder information
Shareholder enquiries should be directed to the Company's
registrars, Capita Asset Services, at their Customer Support
Centre, details as follows:
By phone - UK - 0871 664 0300 (UK calls cost 12p per minute plus
your phone company's access charge).
If you are outside the United Kingdom, please call +44 371 664
0300. Calls from outside the United Kingdom will be charged at the
applicable international rate. The helpline is open between 9.00am
to 5.30pm, Monday to Friday, excluding public holidays in England
and Wales.
By email - ssd@capita.co.uk
By post - Capita Asset Services, The Registry, 34 Beckenham
Road, Beckenham, Kent BR3 4TU.
Further information regarding the various services offered by
Capita Asset Services, including the Share Portal and Share Dealing
Service, can be obtained from the above or directly from Capita's
website www.capitaassetservices.com or
www.capitashareportal.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR UAVNRNRAAUAA
(END) Dow Jones Newswires
November 22, 2016 02:00 ET (07:00 GMT)
Scapa (LSE:SCPA)
Historical Stock Chart
From Apr 2024 to May 2024
Scapa (LSE:SCPA)
Historical Stock Chart
From May 2023 to May 2024